Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial to Evaluate Safety and Efficacy of Combination of Liposomal Irinotecan (Nal-IRI; ONIVYDE®) and Cisplatin in Patients With Advanced or Metastatic Solid Malignancies (ICONIC Study)

NCT07782346 is registered in ClinicalTrials.gov with National Health Research Institutes, Taiwan as lead sponsor.

NCT NCT07782346
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07782346 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial to Evaluate Safety and Efficacy of Combination of Liposomal Irinotecan (Nal-IRI; ONIVYDE®) and Cisplatin in Patients With Advanced or Metastatic Solid Malignancies (ICONIC Study)
Lead sponsor
National Health Research Institutes, Taiwan
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
December 31, 2032
Enrollment
44 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid malignancies